71 related articles for article (PubMed ID: 25397535)
1. Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA.
Bianco C; Meini G; Rossetti B; Lamonica S; Mondi A; Belmonti S; Fanti L; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19791. PubMed ID: 25397535
[TBL] [Abstract][Full Text] [Related]
2. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.
Rossetti B; Meini G; Bianco C; Lamonica S; Mondi A; Belmonti S; Fanti I; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
J Clin Virol; 2017 Jun; 91():18-24. PubMed ID: 28395180
[TBL] [Abstract][Full Text] [Related]
3. Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load.
Sterrantino G; Zaccarelli M; Prati F; Boschi A; Sighinolfi L; Borghi V
J Int AIDS Soc; 2014; 17(4 Suppl 3):19774. PubMed ID: 25397518
[TBL] [Abstract][Full Text] [Related]
4. Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial.
Lafeuillade A; Assi A; Poggi C; Bresson-Cuquemelle C; Jullian E; Tamalet C
AIDS Res Ther; 2014; 11(1):33. PubMed ID: 25320633
[TBL] [Abstract][Full Text] [Related]
5. The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART.
Kiselinova M; Anna M; Malatinkova E; Vervish K; Beloukas A; Messiaen P; Bonczkowski P; Trypsteen W; Callens S; Verhofstede C; De Spiegelaere W; Vandekerckhove L
J Int AIDS Soc; 2014; 17(4 Suppl 3):19823. PubMed ID: 25397567
[TBL] [Abstract][Full Text] [Related]
6. Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.
Lam YM; McBride KL; Amin J; Cordery DV; Kelleher AD; Cooper DA; Koelsch KK
PLoS One; 2012; 7(3):e31990. PubMed ID: 22396745
[TBL] [Abstract][Full Text] [Related]
7. Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.
Arribas J; Rizzardini G; Arasteh K; Zurawski C; Dietz C; Pontani D; Garner W; Nguyen T
J Int AIDS Soc; 2014; 17(4 Suppl 3):19805. PubMed ID: 25397549
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
Fabbiani M; Mondi A; Colafigli M; D'Ettorre G; Paoletti F; D'Avino A; Ciccarelli N; Sidella L; Murri R; Fortuna S; Vullo V; Cauda R; De Luca A; Di Giambenedetto S
Scand J Infect Dis; 2014 Jan; 46(1):34-45. PubMed ID: 24161018
[TBL] [Abstract][Full Text] [Related]
9. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral therapy (ART) management of Low-Level Viremia in Taiwan (ALLEVIATE).
Cheng CY; Luo YZ; Wu PY; Liu WC; Yang SP; Zhang JY; Cheng SH; Hung CC
J Int AIDS Soc; 2014; 17(4 Suppl 3):19785. PubMed ID: 25397529
[TBL] [Abstract][Full Text] [Related]
11. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Eron JJ; Young B; Cooper DA; Youle M; Dejesus E; Andrade-Villanueva J; Workman C; Zajdenverg R; Fätkenheuer G; Berger DS; Kumar PN; Rodgers AJ; Shaughnessy MA; Walker ML; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Xu X; Sklar P;
Lancet; 2010 Jan; 375(9712):396-407. PubMed ID: 20074791
[TBL] [Abstract][Full Text] [Related]
12. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
[TBL] [Abstract][Full Text] [Related]
13. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial.
Katlama C; Lambert-Niclot S; Assoumou L; Papagno L; Lecardonnel F; Zoorob R; Tambussi G; Clotet B; Youle M; Achenbach CJ; Murphy RL; Calvez V; Costagliola D; Autran B;
AIDS; 2016 Jan; 30(2):221-30. PubMed ID: 26684819
[TBL] [Abstract][Full Text] [Related]
14. Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study.
Seang S; Fourati S; Keita Y; Blanc C; Tubiana R; Schneider L; Valantin MA; Caby F; Calin R; Lambert-Niclot S; Marcelin AG; Calvez V; Costagliola D; Katlama C
J Antimicrob Chemother; 2014 Dec; 69(12):3356-9. PubMed ID: 25056835
[TBL] [Abstract][Full Text] [Related]
15. Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.
Stephan C; Baldauf HM; Barry J; Giordano FA; Bartholomae CC; Haberl A; Bickel M; Schmidt M; Laufs S; Kaderali L; Keppler OT
J Antimicrob Chemother; 2014 Oct; 69(10):2809-18. PubMed ID: 24962031
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of protease inhibitor-based regimens in HIV-infected Thai children failing first-line treatment.
Wattanutchariya N; Sirisanthana V; Oberdorfer P
HIV Med; 2013 Apr; 14(4):226-32. PubMed ID: 23094820
[TBL] [Abstract][Full Text] [Related]
17. Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis.
Stellbrink HJ; Antinori A; Pozniak A; Flamm J; Bredeek F; Patel K; Garner W; Piontkowsky D
J Int AIDS Soc; 2014; 17(4 Suppl 3):19793. PubMed ID: 25397537
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM;
J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
[TBL] [Abstract][Full Text] [Related]
19. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
Pinnetti C; Di Giambenedetto S; Maggiolo F; Lorenzini P; Fabbiani M; Tommasi C; Latini A; Ammassari A; Loiacono L; Sterrantino G; Bellagamba R; Boumis E; Antinori A; Zaccarelli M
J Int AIDS Soc; 2014; 17(4 Suppl 3):19812. PubMed ID: 25397556
[TBL] [Abstract][Full Text] [Related]
20. Short communication: Effectiveness at 48 weeks of switching from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV type 1-infected patients in a Brazilian cohort.
Westin MR; Biscione F; Ribeiro KM; Greco DB; Tupinambás U
AIDS Res Hum Retroviruses; 2014 Feb; 30(2):113-7. PubMed ID: 23875625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
